Avsar.

Healthcare · Q2FY27 · Consolidated

Beta Drugs' Q2 profit was driven mainly by operations

Consolidated operating profit of Rs 30.28 cr translated into Rs 19.28 cr of net profit after a 25.19% tax rate.

By Ashutosh

Filed 22 Oct 2026, 11:13 IST · Beta Drugs Ltd (BETA)

Key takeaways

  • Beta Drugs reported consolidated net profit of Rs 19.28 in Q2FY27, with EPS of Rs 16.59.
  • Operating profit of Rs 30.28 represented a 22.02% operating margin on revenue of Rs 137.49.
  • Interest of Rs 1.64, depreciation of Rs 4.61 and tax of Rs 6.49 reduced operating profit to reported net profit.

Price around the results

Operating profit was the main earnings driver

Beta Drugs' consolidated revenue was Rs 137.49, generating operating profit of Rs 30.28 and an operating margin of 22.02%. Other income was Rs 1.75, well below operating profit, so the reported result was primarily supported by the operating business.

Below-operating costs reduced profit conversion

Interest of Rs 1.64 and depreciation of Rs 4.61 took profit before tax to Rs 25.78. Tax of Rs 6.49, equal to a 25.19% tax rate, brought net profit to Rs 19.28.

Q2FY27 earnings translate to Rs 16.59 EPS

The consolidated result delivered basic EPS of Rs 16.59. The earnings bridge shows that depreciation, financing costs and tax were material deductions between operating profit of Rs 30.28 and net profit of Rs 19.28.

Q2FY27 at a glance

Consolidated figures as filed with NSE — filed ahead of third-party databases, not yet independently cross-checked.

Line itemQ2FY27
Revenue₹137 cr
Other income₹2 cr
Expenses₹107 cr
Operating profit₹30 cr
Operating margin (%)22.02%
Interest₹2 cr
Depreciation₹5 cr
Profit before tax₹26 cr
Tax₹6 cr
Net profit₹19 cr
EPS (₹)₹16.59

How the stock reacted

WindowStockvs NIFTY
Results day-3.81%-3.42%

Volume on the results session was 2.22× its 20-day average.

What to watch

  • Whether operating margin holds at or above 22.02%.
  • Whether the tax rate remains close to 25.19%.
  • Whether EPS remains at Rs 16.59.